Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
Stefan K. Barta, Jasmine Zain, Alexander W. MacFarlane, et al.
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 19, Iss. 6, pp. 356-364.e3
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 67
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
Bin Zhao, Hong Zhao, Jiaxin Zhao
Therapeutic Advances in Medical Oncology (2020) Vol. 12
Open Access | Times Cited: 126
Targeting immune checkpoints in hematological malignancies
Basit Salik, Mark J. Smyth, Kyohei Nakamura
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 106
Peripheral T cell lymphomas: from the bench to the clinic
Danilo Fiore, Luca Vincenzo Cappelli, Alessandro Broccoli, et al.
Nature reviews. Cancer (2020) Vol. 20, Iss. 6, pp. 323-342
Closed Access | Times Cited: 105
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
Wei Xie, L. Jeffrey Medeiros, Shaoying Li, et al.
Current Hematologic Malignancy Reports (2020) Vol. 15, Iss. 4, pp. 372-381
Closed Access | Times Cited: 70
Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
N. Nora Bennani, Hyo Jin Kim, Levi D. Pederson, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 6, pp. e004984-e004984
Open Access | Times Cited: 54
PET/CT in Non-Hodgkin Lymphoma: An Update
Lucia Zanoni, Davide Bezzi, Cristina Nanni, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 320-351
Closed Access | Times Cited: 42
Recent Treatment Strategies and Molecular Pathways in Resistance Mechanisms of Antiangiogenic Therapies in Glioblastoma
Md. Ataur Rahman, Meser M. Ali
Cancers (2024) Vol. 16, Iss. 17, pp. 2975-2975
Open Access | Times Cited: 9
Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management
Shin Yeu Ong, Jasmine M. Zain
American Journal of Hematology (2024) Vol. 99, Iss. 3, pp. 439-456
Open Access | Times Cited: 8
The rapidly changing landscape in mature T‐cell lymphoma (MTCL) biology and management
Enrica Marchi, Owen A. O’Connor
CA A Cancer Journal for Clinicians (2019) Vol. 70, Iss. 1, pp. 47-70
Open Access | Times Cited: 62
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 54
Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
Yumei Gao, Simeng Hu, Ruoyan Li, et al.
JCI Insight (2023) Vol. 8, Iss. 4
Open Access | Times Cited: 18
Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
Robert Stuver, Alison J. Moskowitz
Cancers (2023) Vol. 15, Iss. 3, pp. 589-589
Open Access | Times Cited: 16
Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
Jingli Lü, Lulu Li, Yan Lan, et al.
Cancer Medicine (2019) Vol. 8, Iss. 18, pp. 7503-7515
Open Access | Times Cited: 49
Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
Yang Xu, Ping Li, Yang Liu, et al.
Cancer Communications (2022) Vol. 42, Iss. 6, pp. 493-516
Open Access | Times Cited: 23
PTCL, NOS: An update on classification, risk-stratification, and treatment
J. Weiss, John Reneau, Ryan A. Wilcox
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
Therapie der nodalen peripheren T-Zell-Lymphome
Till Braun, Gerald Wulf
Deleted Journal (2025)
Closed Access
JAK3A573VandJAK3M511Imutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway
Ning Lou, Mengwei Yang, Zucheng Xie, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 4, pp. e010783-e010783
Open Access
Biomarker-driven management strategies for peripheral T cell lymphoma
Erin Mulvey, Jia Ruan
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 35
T-cell lymphoma secondary to checkpoint inhibitor therapy
Kartik Anand, Joe Ensor, Sai Ravi Pingali, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000104-e000104
Open Access | Times Cited: 34
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management
Jasmine M. Zain, Paul Hanona
American Journal of Hematology (2021) Vol. 96, Iss. 8, pp. 1027-1046
Open Access | Times Cited: 31
Peripheral T-Cell Lymphomas: Therapeutic Approaches
David Sibon
Cancers (2022) Vol. 14, Iss. 9, pp. 2332-2332
Open Access | Times Cited: 19
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors
Matthew R. Zibelman, Alexander W. MacFarlane, Kimberly Costello, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs)
Alison J. Moskowitz, Robert Stuver, Steven M. Horwitz
Blood (2024) Vol. 144, Iss. 18, pp. 1887-1897
Closed Access | Times Cited: 4
Current and upcoming treatment approaches to uncommon subtypes of PTCL (EATL/MEITL, SPTCL, HSTCL)
Enrica Marchi, Jeffrey W. Craig, Matko Kalac
Blood (2024) Vol. 144, Iss. 18, pp. 1898-1909
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top